Cervical Cancer Data Inject Fresh Life Into Sanofi's Libtayo
More Positive Phase III Findings For Regeneron-Partnered PD-1 Inhibitor
Libtayo is the first immunotherapy to demonstrate an improvement in OS, PFS and ORR in advanced cervical cancer and approval in this indication could kickstart its lackluster sales to date.
You may also be interested in...
The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.
In addition to securing a key position in first-line disease, Keytruda has potential to expand its presence in later lines with combination data from Seagen/Genmab’s Tivdak.
Combining Merck & Co’s pembrolizumab with chemotherapy first-line improves survival and PFS in metastatic cervical cancer, reinforcing its position in a condition in the sights of a number of other companies, although usually in later lines of therapy.